MOTS-c is a mitochondrial-derived peptide studied mostly in cells, animals, and small human physiology studies. Oral or sublingual MOTS-c products are marketed online, but available human research does not establish that oral MOTS-c is absorbed, effective, or safe as a treatment.1 2 7 A licensed clinician can help put metabolic goals in context.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →Can MOTS-c be taken orally?
You may find oral MOTS-c sold as pills, capsules, drops, or strips. MOTS-c is investigational and not an FDA-approved treatment. But “sold orally” is not the same as proven to work orally: the available MOTS-c human studies do not establish oral absorption, oral bioavailability, clinical benefit, or long-term safety for these products.2 7
Direct answer for pills, capsules, drops, and sublingual strips
There is no established human evidence that native MOTS-c in a pill, capsule, drop, sublingual strip, or buccal strip reaches the bloodstream in a reliable amount and produces a patient-important outcome. The Phase 2 MOTS-c trial record does not report results for an oral product.7
Why oral availability is separate from biological interest
A compound can be biologically interesting in a lab or animal model and still lack a workable oral form in people. The foundational MOTS-c study reported metabolic findings in mice and cells, so those results cannot establish that a marketed oral product changes weight, insulin resistance, endurance, or aging outcomes in humans.1
What is MOTS-c?
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a 16-amino-acid mitochondrial-derived peptide, meaning its sequence comes from mitochondrial DNA rather than the nuclear DNA that holds most human genes.1
Mitochondria are often called a cell’s energy centers. Researchers study mitochondrial-derived peptides because they may act as signals between cellular energy stress and broader metabolic pathways. That is why MOTS-c appears in discussions of exercise response, metabolic stress, insulin sensitivity, and aging biology—but these research topics are not established treatment indications.1 2
What does the research actually show in humans?
The direct answer is that human evidence is limited and mostly observational or physiology-focused. The studies available measure a person’s own circulating MOTS-c levels; they do not show that taking oral or injectable MOTS-c improves health outcomes.2 3 4
Exercise and physiologic-response studies
A 2021 randomized study found that acute endurance exercise stimulated circulating mitochondrial-derived peptides in humans, including MOTS-c. This helps researchers understand an exercise response; it does not show that MOTS-c supplementation reproduces exercise effects.2
In breast cancer survivors, researchers also measured MOTS-c in an exercise study. This was human physiology research, not a trial showing that MOTS-c products treat cancer, improve performance, or change body weight.3
Studies measuring MOTS-c in health conditions
Other human studies have examined circulating MOTS-c in specific clinical settings. A 2022 study measured levels in people with breast cancer treated with metformin, while a 2025 study measured MOTS-c during heat stress and calf-muscle immobilization in active men.4 5 These studies cannot tell us whether taking MOTS-c is helpful or safe.
A study in people with type 2 diabetes and revascularized coronary artery disease examined mitochondrial-derived peptide-c in relation to platelet reactivity and clinical outcomes. That is association and prognostic research, not evidence that MOTS-c is a cardiovascular treatment.6 8
What the current Phase 2 trial may clarify
A registered Phase 2 trial plans to study MOTS-c for insulin sensitivity in 120 adults with prediabetes and overweight or obesity. Recruiting status means the question is still being tested; until results are reported, it cannot establish a benefit, a safe dose, or an effective route of administration.7
What has been shown only in cells or animals?
The strongest treatment-effect findings for MOTS-c remain preclinical. In the original 2015 work, MOTS-c was studied in cells and mice, where researchers reported effects related to metabolic homeostasis, diet-related obesity, and insulin resistance.1
Researchers have proposed mechanisms involving AMPK, a cellular energy-sensing pathway, and the folate-methionine cycle. Mechanisms can help form a research hypothesis, but they do not prove that a product will deliver the same effect in people.1
Oral MOTS-c vs injectable MOTS-c: what is known?
Neither route has an established patient-use evidence base. No route has proven clinical outcomes for MOTS-c in the supplied human research, and convenience claims should not be confused with absorption or effectiveness data.2 7
| Format | What is marketed or claimed | What human evidence establishes | Key unanswered question |
|---|---|---|---|
| Oral pill or capsule | Convenient swallowed format | No established oral absorption or clinical-outcome data for native MOTS-c | How much, if any, intact peptide reaches circulation |
| Sublingual or buccal strip | Absorption through tissues in the mouth | No supplied human trial establishes effectiveness of sublingual or buccal MOTS-c | Whether the product reaches a reliable active level |
| Drops | Often marketed as an oral or under-the-tongue option | No supplied human outcomes data | Whether route and formulation change absorption |
| Injectable MOTS-c | Often discussed in research-peptide settings | Human studies cited here do not establish MOTS-c injection as a treatment | Safety, benefit, dose, and long-term outcomes |
A route can only be considered evidence-based when research directly evaluates that formulation, how it is absorbed, and whether it changes meaningful outcomes. The human MOTS-c studies discussed here do not answer those questions for marketed oral, sublingual, buccal, or injectable products.2 3 7
Why are many peptides difficult to take by mouth?
Peptides are short chains of amino acids. Digestive enzymes act quickly, so a swallowed peptide may be broken down before it can enter the bloodstream intact. Whether a specific formulation solves that problem must be shown in direct pharmacokinetic and clinical studies, not assumed from a product format.1 7
Sublingual and buccal products aim to avoid part of the digestive process by placing a compound in the mouth. That route still needs direct evidence for native MOTS-c: a claim about a strip’s convenience does not establish reliable absorption or patient benefit.7
Is MOTS-c approved or established as a treatment?
No. MOTS-c has no established approved indication for weight loss, prediabetes, insulin resistance, exercise performance, or longevity. A registered human clinical trial is an important research step, but it is not evidence of effectiveness and is not an approval decision.7
What are the safety questions with oral MOTS-c products?
The main issue is uncertainty. Long-term safety is unknown because the cited human research did not test oral, sublingual, buccal, or injectable MOTS-c as routine treatment, and it did not establish interactions with prescription medicines.2 4 7
That uncertainty matters most for people who are pregnant, breastfeeding, managing diabetes, using glucose-lowering medicines, living with cardiovascular disease, or receiving cancer care. Those situations call for individualized medical guidance, not online self-experimentation.2 4 7 For a broader discussion of reported concerns, see our guide to MOTS-c side effects and our overview of MOTS-c injections.
What should patients consider instead for metabolism or weight?
If your goal is better metabolic health, start with standard testing rather than an unproven peptide. A clinician may use fasting glucose, A1C, blood pressure, medication history, sleep, nutrition, activity, and weight trends to understand insulin resistance or prediabetes risk.7
Our guides to insulin resistance treatment, prediabetes, and the A1C blood sugar test can help you prepare for that conversation. For people considering any peptide online, read our patient guide on how to find a legitimate peptide source before making a decision.
At Chia, we offer clinician-reviewed telehealth care for treatments in our current catalog, but we do not offer MOTS-c. A medical evaluation is needed before any prescription treatment, and a prescription is never guaranteed.
Frequently asked questions about oral MOTS-c
No. MOTS-c is a mitochondrial-derived peptide under investigation. GLP-1 receptor agonists are a separate medication class being studied in clinical trials.10
No. MOTS-c is not an approved treatment for weight loss or prediabetes. A Phase 2 study is recruiting people with prediabetes and overweight or obesity, but a registered trial does not mean the treatment has been shown to work.7
References
- 1.Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015.
- 2.von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of Applied Physiology. 2021.
- 3.Dieli-Conwright CM, Sami N, Norris MK, et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific Reports. 2021.
- 4.Cuyàs E, Verdura S, Martin-Castillo B, et al. Circulating levels of MOTS-c in patients with breast cancer treated with metformin. Aging. 2022.
- 5.Elhusseiny R, Ihsan M, Labidi M, et al. Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization. Medicine and Science in Sports and Exercise. 2025.
- 6.Ikonomidis I, Katogiannis K, Kyriakou E, et al. β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. Journal of Thrombosis and Thrombolysis. 2020.
- 7.ClinicalTrials.gov. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745). 2026.
- 8.ClinicalTrials.gov. Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD (NCT04027712). 2026.
- 9.ClinicalTrials.gov. Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation (NCT07678073). 2026.
- 10.ClinicalTrials.gov. The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination (NCT03878706). 2019.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
